116 related articles for article (PubMed ID: 8148056)
1. Mutations and expression of the p53 gene in rat bladder carcinomas and cell lines.
Asamoto M; Mann AM; Macatee TL; Cohen SM
Mol Carcinog; 1994 Apr; 9(4):236-44. PubMed ID: 8148056
[TBL] [Abstract][Full Text] [Related]
2. Mutation and altered expression of p53 genes in experimental rat bladder tumor cells.
Jones RF; Matuszyk J; Debiec-Rychter M; Wang CY
Mol Carcinog; 1994 Feb; 9(2):95-104. PubMed ID: 8142014
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53.
Lee CC; Ichihara T; Yamamoto S; Wanibuchi H; Sugimura K; Wada S; Kishimoto T; Fukushima S
Carcinogenesis; 1999 Sep; 20(9):1697-708. PubMed ID: 10469613
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Masui T; Dong Y; Yamamoto S; Takada N; Nakanishi H; Inada K; Fukushima S; Tatematsu M
Cancer Lett; 1996 Jul; 105(1):105-12. PubMed ID: 8689624
[TBL] [Abstract][Full Text] [Related]
8. p53 mutation is infrequent and might not give a growth advantage in rat bladder carcinogenesis in vivo.
Asamoto M; Mann AM; Cohen SM
Carcinogenesis; 1994 Mar; 15(3):455-8. PubMed ID: 8118928
[TBL] [Abstract][Full Text] [Related]
9. mRNA and protein expression of p53 mutations in human bladder cancer cell lines.
Kawasaki T; Tomita Y; Watanabe R; Tanikawa T; Kumanishi T; Sato S
Cancer Lett; 1994 Jul; 82(1):113-21. PubMed ID: 8033064
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines.
Asamoto M; Cohen SM
Cancer Lett; 1994 Aug; 83(1-2):201-7. PubMed ID: 8062216
[TBL] [Abstract][Full Text] [Related]
11. Antisense RNA-mediated reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial cells.
Okamoto M; Hattori K; Fujimoto K; Tanaka Y; Gloosby CL; Oyasu R
Carcinogenesis; 1998 Jan; 19(1):73-9. PubMed ID: 9472696
[TBL] [Abstract][Full Text] [Related]
12. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
13. Morphologic transformation of the C3H 10T1/2 cell line is accompanied by altered expression of the p53 tumor suppressor gene.
Coleman WB; Grisham JW; Smith GJ
Carcinogenesis; 1994 Feb; 15(2):145-52. PubMed ID: 8313500
[TBL] [Abstract][Full Text] [Related]
14. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
[TBL] [Abstract][Full Text] [Related]
15. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Masui T; Don I; Takada N; Ogawa K; Shirai T; Fukushima S
Carcinogenesis; 1994 Oct; 15(10):2379-81. PubMed ID: 7955081
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
18. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bartek J; Iggo R; Gannon J; Lane DP
Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291
[TBL] [Abstract][Full Text] [Related]
19. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
